RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063. We believe PMX-30063 is the first and only small-molecule mimetic of host defense proteins in clinical development intended for systemic administration, with a novel mechanism of action distinct from other antibiotic drugs and believed to make bacterial resistance unlikely to develop. The data from the study demonstrate that administration of multiple doses of PMX-30063 at varying levels are safe and well-tolerated. The doses and blood levels of drug achieved in this study suggest that a beneficial therapy may exist. Further clinical development is planned to continue for the initial indication for this drug as a broad treatment for Staphylococcus infections.
